In targeting glioblastoma cells, CAR-T cells modified with a targeted-quadruple-mutant of IL13 was combined with fluorescent therapeutic NPs and targeted to IL13Rα2 overexpressed glioblastoma cells. Here, IL13 is linked to glioblastoma.